NEWTOWN, Pa.--(BUSINESS WIRE)--Helius Medical Technologies, Inc. (CSE: HSM) (“HMT”, “Helius” or the “Company”) is pleased to announce today that it has obtained investigational testing authorization from Health Canada for its PoNSTM device. Helius intends to initiate a study of the PoNSTM device in the treatment of symptoms associated with Multiple Sclerosis (“MS”). On institutional review board (IRB) approval, this study is scheduled to commence at the Montreal Neurological Institute. The PoNSTM, an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue, is initially being studied for the treatment of balance disorder symptoms caused by Traumatic Brain Injury (“TBI”) and MS.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
